AGENUS INC Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AGENUS INC stock issued during period, value, new issues for the quarter ending 2026-06-30 was $14.10M, a 15.37% increase year-over-year.
- AGENUS INC stock issued during period, value, new issues for the quarter ending 2026-03-31 was $996.00K, a 84.30% decline year-over-year.
- AGENUS INC stock issued during period, value, new issues for the quarter ending 2025-09-30 was $8.97M, a 32.32% increase year-over-year.
- AGENUS INC stock issued during period, value, new issues for the quarter ending 2025-06-30 was $12.22M, a 513.92% increase year-over-year.
- AGENUS INC stock issued during period, value, new issues for fiscal 2025 was $36.14M, a 9.43% increase from fiscal 2024.
- AGENUS INC stock issued during period, value, new issues for fiscal 2024 was $33.02M, a 75.20% decline from fiscal 2023.
- AGENUS INC stock issued during period, value, new issues for fiscal 2023 was $133.16M, a 34.22% increase from fiscal 2022.
- AGENUS INC stock issued during period, value, new issues for fiscal 2022 was $99.21M, a 49.80% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $14.10M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $996.00K 10-Q · filed 2026-08-07 | |
| 2025-12-31 | $36.14M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $8.97M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $12.22M 10-Q · filed 2026-08-07 | |
| 2025-03-31 | $6.34M 10-Q · filed 2026-08-07 | |
| 2024-12-31 | $33.02M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $6.78M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $1.99M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $17.17M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $133.16M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $20.35M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $42.25M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $60.58M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $99.21M 10-K · filed 2025-03-17 | |
| 2022-09-30 | $27.83M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $28.24M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $19.18M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $197.65M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $77.43M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $9.15M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $60.86M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $156.42M 10-K · filed 2023-03-16 | |
| 2020-09-30 | $46.40M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $19.91M 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $65.12M 10-Q · filed 2021-11-09 | |
| 2018-12-31 | $44.92M 10-K · filed 2021-03-16 | |
| 2018-09-30 | $243.00K 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $22.64M 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $5.26M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $5.56M 10-K · filed 2020-03-16 | |
| 2016-12-31 | $2.17M 10-K · filed 2019-03-18 | |
| 2015-12-31 | $74.67M 10-K · filed 2018-03-16 | |
| 2014-12-31 | $600.66K 10-K · filed 2017-03-16 | |
| 2013-12-31 | $16.99M 10-K · filed 2016-03-15 | |
| 2012-12-31 | $10.46M 10-K · filed 2015-03-16 | |
| 2011-12-31 | $7.50M 10-K · filed 2014-03-07 | |
| 2010-12-31 | $8.65M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |